Published Paper Details:

Lymphoma is a complex group of hematologic malignancies originating from lymphocytes, encompassing Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Each subtype presents distinct biological, clinical, and pathological characteristics, necessitating precise diagnostic and therapeutic approaches. Advances in molecular biology and immunology have significantly enhanced our understanding of the mechanisms underlying lymphomagenesis, including genetic mutations, epigenetic alterations, and immune dysregulation. These discoveries have led to refined classification systems and improved risk stratification.Diagnostic approaches for lymphoma have progressed with the integration of advanced imaging, immunophenotyping, and molecular profiling techniques, enabling more accurate subtype identification and prognostication. Standard therapies, such as chemotherapy and radiotherapy, remain foundational, but the treatment landscape has shifted with the advent of targeted therapies and immunotherapeutics. Monoclonal antibodies, immune checkpoint inhibitors, and bispecific T-cell engagers have improved response rates and survival outcomes. Furthermore, chimeric antigen receptor (CAR)-T cell therapy has shown remarkable efficacy in relapsed or refractory cases, offering durable remissions in patients with limited options.This review synthesizes recent progress in lymphoma research and clinical care, emphasizing the critical role of precision medicine and emerging therapeutics in addressing unmet needs.